Evidence

BMI and type 2 diabetes: how much do ethnicity, age, and sex matter?

Making sense of abnormal liver blood tests: a MASLD heuristic for primary care

Around one in five adults have abnormal liver blood results. However, in the BALLETS primary care group, only 2.5% had a specific liver disease.

REIMAGINE-2: how effective is combination therapy for type 2 diabetes?

The phase 3 diabetes endpoint for retatrutide has been met, as shown by TRANSCEND-T2D-1

The TRANSCEND-T2D-1 trial for Retatrutide i8n T2D was just published in The Lancet - big news. But what are the benefits of a triple agonist?

ACHIEVE-5 phase 3 trial shows superiority of GLP-1 RA alongside basal insulin

ACHIEVE-5 is the first phase 3 trial that tests if the once-daily oral GLP-1 RA (orforglipron) can work alongside basal insulin (with no restriction on food or water).

NG28 NICE GUIDELINES: The Flozin-First Era, and 810,000 More GLP-1 Patients

The February 2026 update to NG28 ends that era. Most newly diagnosed patients will now be offered an SGLT-2 inhibitor alongside metformin from the outset.

ACHIEVE-4: what the mortality signal actually tells UK clinicians

This week’s headline result is also this week's most over-hyped: 57% lower all-cause mortality with orforglipron compared to insulin glargine, and what these findings actually mean.

FreeDM2: Real-time CGM for type 2 diabetes on basal insulin.

A UK randomised trial in the largest insulin-treated type 2 cohort that NICE guidelines NG28 doesn't currently fund.

GLP-1 for Alzheimer's? EVOKE trial says no

The EVOKE trials are in, and the answer is no. Novo Nordisk has terminated the programme and discontinued the planned one-year extension of both trials.

GLP-1 Receptor Agonists: Mechanism of Action

How GLP-1 receptor agonists drive weight loss across the brain, gut, and metabolism.

SGLT2i vs GLP-1 RA: which one offers more kidney protection?

Both SGLT2 inhibitors and GLP-1 receptor agonists protect the kidneys in type 2 diabetes. A large new JAMA study is the closest we have to a head-to-head answer — and the results are not straightforward.

MHRA Safety Update: Semaglutide and the Risk of Rare Vision Loss

If you prescribe semaglutide, you need to know about this MHRA safety update on the risk of rare vision loss.

The GLP-1 revolution: the good, the bad and the ugly

If it feels like your practice is increasingly dominated by patients asking for the 'miracle jab,' you aren't alone. A comprehensive primary care update on GLP-1 receptor agonists in 2026.